Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ: CRBP · Life Sciences · 6 alerts · CIK 1595097

Share price
$3.38Close, Nov 16
Market cap
$69.5M
Shares outstanding
20.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Corbus Pharmaceuticals Holdings, Inc. filings on SEC EDGAR ↗

8:10 AM ET 8-K
Clinical Trial Data

Corbus Pharmaceuticals Holdings Clinical Trial Data

Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.

Term
16 weeks

“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.